Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Predicting the Unpredictable – Taming the Impulse to Treat

Philip Seo, MD, MHS  |  Issue: January 2019  |  January 17, 2019

The Inflection Point

Everett - Art / shutterstock.com

Benjamin Franklin
Everett – Art / shutterstock.com

In medicine, as in life, it is often too early to act, until it is suddenly—irrevocably—too late. In clinical therapeutics, the trick is to catch patients at the inflection point, the moment at which the patient’s health is transitioning from good to bad. Finding that inflection point, that’s the trick.

We all know the penalties of waiting too long. Years ago, I was confronted by a patient of mine who had a long-time diagnosis of microscopic polyangiitis. She had come into my clinic after years of falling in and out of the medical system, with the gaps patched by too much prednisone. I straightened out her regimen, tapered her prednisone and dutifully recorded that she was in remission. When I told her this, she became angry. How could she be in remission? She still became winded when she walked up a flight of steps, she still had trouble bending forward to pick up the mail off her stoop. When would the medications start to work?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

I realized then that we had been talking past each other for months. I turned away from the computer to face her, and I told her as gently as I could that for me, remission just meant her disease was no longer creating new problems. The medications did not reverse the damage caused by her diagnosis when the disease was active or the damage caused by the drugs that had been used over the years to manage her disease. For these, we were dependent on her body’s natural healing processes, but the healing did not occur spontaneously. It would require time and hard work on her part to return to the level of function that she craved.

I never saw her again.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Benjamin Franklin, Rheumatologist?

Founding Father of the United States Benjamin Franklin, was many things. He was a politician, diplomat, humorist, scientist and inventor. Sometimes, I wonder if he was also a rheumatologist.

In 1733, Mr. Franklin faced the problem of fires in his adopted city of Philadelphia. At the time, when a building was on fire, good doers would show up and try to help. And just like when a code blue is called over the hospital intercom, the people who show up might be a motley crew of varying skills and interests, leaving the fate of the burgeoning Philadelphia cityscape in the hands of happenstance.

Unable to persuade the City of Brotherly Love that it needed a more organized way of responding to threats to the burgeoning cityscape, he wrote an anonymous letter to his own newspaper, The Pennsylvania Gazette. “In the first Place, as an Ounce of Prevention is worth a Pound of Cure, I would advise ’em to take care how they suffer living Coals in a full Shovel … when your Stairs being in Flames, you may be forced (as I once was) to leap out of your Windows, and hazard your Necks to avoid being oven-roasted.”2

Rheumatologists also know that an ounce of prevention is worth a pound of cure. No amount of etanercept will heal the deformities of a burnt out rheumatoid arthritis; no amount of cyclophosphamide will heal the kidneys of a patient with microscopic polyangiitis on dialysis. We, therefore, start patients with mild disease on mild drugs, hoping to prevent the severe complications that await.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:early arthritisVery Early Rheumatoid Arthritis

Related Articles
    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Targeted Therapy for Scleroderma Fibrosis

    October 11, 2016

    Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a prevalence in North America of approximately 300 per 1 million people, SSc is associated with significant morbidity and high rates of mortality.1 Patients with scleroderma have four times greater mortality than age- and sex-matched controls, with…

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    February 17, 2018

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

    Lessons Learned from Two Scleroderma Lung Studies (Plus a Third That’s Recruiting Sites)

    August 16, 2019

    Historically, the early approach for treating interstitial lung disease (ILD) due to systemic sclerosis (SSc) involved immunosuppressant therapy, primarily with cytotoxic agents.1 Glucocorticoids in combination with another immunosuppressant agent, such as oral azathioprine or cyclophosphamide, were often used to treat patients with severe, progressive SSc-ILD.2 However, direct evidence to support this thera­peutic approach was lacking…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences